Skip to main content

Table 3 Associations with FIB-4 score among HIV/HCV co-infected individuals (n = 89)

From: Genotypic distribution and hepatic fibrosis among HIV/HCV co-infected individuals in Southern China: a retrospective cross-sectional study

Correlate    β Coefficient (95 % CI) p-value β Adjusted Coefficient (95 % CI) p-value
Age, years    0.10 (0.03,0.17) 0.005 0.09 (0.030, 0.153) 0.004
Unemployed    1.24 (0.36,2.13) 0.006 1.07 (0.26, 1.87) 0.010
HCV Genotype 3a    2.15 (1.01,3.28) <0.001 2.18 (1.17, 3.18) <0.001
Immunosuppression ART Naïve (n = 52) ART (n = 37)     
 CD4+ ≤ 50 cells/μL 15 0 2.00 (0.02,3.98) 0.048 2.39 (0.73, 4.07) 0.005
 CD4+ 51–200 cells/μL 24 3 1.07 (−0.79,2.92) 0.256 1.30 (−0.25, 2.84) 0.098
 CD4+ 201–350 cells/μL 7 20 1.42 (−0.44,3.27) 0.132 1.65 (0.10, 3.20) 0.037
 CD4+ 351–500 cells/μL 5 9 0.27 (−1.74,2.27) 0.793 0.44 (−1.23, 2.11) 0.600
 CD4+ 501–1000 cells/μL 1 5 Referent   Referent  
  1. Abbreviations: ART antiretroviral therapy, CI confidence interval. For HCV mono-infected patients, HCV genotype 3a was not found to correlate with increased FIB-4 score (p = 0.914). No significant correlations were found with APRI score. Bold p-values are significant at the 0.05 level